FOREWORD

This toxicological profile is prepared in accordance with guidelines* developed by the Agency for Toxic Substances and Disease Registry (ATSDR) and the Environmental Protection Agency (EPA). The original guidelines were published in the *Federal Register* on April 17, 1987. Each profile will be revised and republished as necessary.

The ATSDR toxicological profile succinctly characterizes the toxicologic and adverse health effects information for these toxic substances described therein. Each peer-reviewed profile identifies and reviews the key literature that describes a substance's toxicologic properties. Other pertinent literature is also presented, but is described in less detail than the key studies. The profile is not intended to be an exhaustive document; however, more comprehensive sources of specialty information are referenced.

The focus of the profiles is on health and toxicologic information; therefore, each toxicological profile begins with a relevance to public health discussion which would allow a public health professional to make a real-time determination of whether the presence of a particular substance in the environment poses a potential threat to human health. The adequacy of information to determine a substance's health effects is described in a health effects summary. Data needs that are of significance to the protection of public health are identified by ATSDR.

Each profile includes the following:

(A) The examination, summary, and interpretation of available toxicologic information and epidemiologic evaluations on a toxic substance to ascertain the levels of significant human exposure for the substance due to associated acute, intermediate, and chronic exposures;

(B) A determination of whether adequate information on the health effects of each substance is available or in the process of development to determine levels of exposure that present a significant risk to human health of acute, intermediate, and chronic health effects; and

(C) Where appropriate, identification of toxicologic testing needed to identify the types or levels of exposure that may present significant risk of adverse health effects in humans.

The principal audiences for the toxicological profiles are health professionals at the Federal, State, and local levels; interested private sector organizations and groups; and members of the public.

This profile reflects ATSDR’s assessment of all relevant toxicologic testing and information that has been peer-reviewed. Staffs of the Centers for Disease Control and Prevention and other Federal scientists have also reviewed the profile. In addition, this profile has been peer-reviewed by a nongovernmental panel and was made available for public review. Final responsibility for the contents and views expressed in this toxicological profile resides with ATSDR.

Patrick N. Breysse, Ph.D., CIH
Director, National Center for Environmental Health and
Agency for Toxic Substances and Disease Registry
Centers for Disease Control and Prevention
*Legislative Background*

The toxicological profiles are developed under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended (CERCLA or Superfund). CERCLA section 104(i)(1) directs the Administrator of ATSDR to “…effectuate and implement the health related authorities” of the statute. This includes the preparation of toxicological profiles for hazardous substances most commonly found at facilities on the CERCLA National Priorities List (NPL) and that pose the most significant potential threat to human health, as determined by ATSDR and the EPA. Section 104(i)(3) of CERCLA, as amended, directs the Administrator of ATSDR to prepare a toxicological profile for each substance on the list. In addition, ATSDR has the authority to prepare toxicological profiles for substances not found at sites on the NPL, in an effort to “…establish and maintain inventory of literature, research, and studies on the health effects of toxic substances” under CERCLA Section 104(i)(1)(B), to respond to requests for consultation under section 104(i)(4), and as otherwise necessary to support the site-specific response actions conducted by ATSDR.
## VERSION HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 1994</td>
<td>Final toxicological profile released</td>
</tr>
<tr>
<td>December 2013</td>
<td>Addendum to the toxicological profile released</td>
</tr>
<tr>
<td>February 2018</td>
<td>Update of data in Chapters 2 and 3, and 7</td>
</tr>
</tbody>
</table>
CONTRIBUTORS & REVIEWERS

CHEMICAL MANAGER TEAM

Jennifer Przybyla, Ph.D.  
ATSDR, Division of Toxicology and Human Health Sciences, Atlanta, GA

David W. Wohlers, Ph.D.  
SRC, Inc., North Syracuse, NY
## CONTENTS

FOREWORD .......................................................................................................................... ii
VERSION HISTORY ............................................................................................................... iv
CONTRIBUTORS & REVIEWERS ........................................................................................... v
CONTENTS ............................................................................................................................ vi
LIST OF FIGURES ................................................................................................................ viii
LIST OF TABLES ................................................................................................................... ix

### CHAPTER 1. RELEVANCE TO PUBLIC HEALTH ................................................................. 1
1.1 OVERVIEW AND U.S. EXPOSURES .............................................................................. 1
1.2 SUMMARY OF HEALTH EFFECTS ................................................................................. 2
1.3 MINIMAL RISK LEVELS (MRLs) .................................................................................. 5

### CHAPTER 2. HEALTH EFFECTS ..................................................................................... 9
2.1 INTRODUCTION .............................................................................................................. 9
2.2 DEATH ........................................................................................................................... 41
2.3 BODY WEIGHT .............................................................................................................. 42
2.4 RESPIRATORY .............................................................................................................. 43
2.5 CARDIOVASCULAR ..................................................................................................... 44
2.6 GASTROINTESTINAL .................................................................................................. 44
2.7 HEMATOLOGICAL ....................................................................................................... 45
2.8 MUSCULOSKELETAL ................................................................................................... 46
2.9 HEPATIC ....................................................................................................................... 46
2.10 RENAL ......................................................................................................................... 50
2.11 DERMAL ...................................................................................................................... 51
2.12 OCULAR ...................................................................................................................... 52
2.13 ENDOCRINE ............................................................................................................... 52
2.14 IMMUNOLOGICAL ...................................................................................................... 53
2.15 NEUROLOGICAL ........................................................................................................ 54
2.16 REPRODUCTIVE ........................................................................................................ 57
2.17 DEVELOPMENTAL .................................................................................................... 58
2.18 OTHER NONCANCER ............................................................................................... 61
2.19 CANCER ..................................................................................................................... 61
2.20 GENOTOXICITY ........................................................................................................ 66
2.21 MECHANISMS OF ACTION ....................................................................................... 69

### CHAPTER 3. TOXICOKINETICS, SUSCEPTIBLE POPULATIONS, BIOMARKERS, CHEMICAL INTERACTIONS ........................................................................................................ 72
3.1 TOXICOKINETICS ...................................................................................................... 72
  3.1.1 Absorption ............................................................................................................. 72
  3.1.2 Distribution ............................................................................................................. 74
  3.1.3 Metabolism ............................................................................................................ 77
  3.1.4 Excretion ............................................................................................................... 80
  3.1.5 Physiologically Based Pharmacokinetic (PBPK)/Pharmacodynamic (PD) Models .................. 82
  3.1.6 Animal-to-Human Extrapolations ....................................................................... 82
3.2 CHILDREN AND OTHER POPULATIONS THAT ARE UNUSUALLY SUSCEPTIBLE ........ 82
3.3 BIOMARKERS OF EXPOSURE AND EFFECT ............................................................. 83
  3.3.1 Biomarkers of Exposure ....................................................................................... 84
  3.3.2 Biomarkers of Effect ............................................................................................ 86
3.4 INTERACTIONS WITH OTHER CHEMICALS .............................................................. 87
# LIST OF FIGURES

1-1. Health Effects Found in Animals Following Inhalation Exposure to Chlordane ................. 2

1-2. Health Effects Found in Animals Following Oral Exposure to Chlordane ......................... 3

1-3. Summary of Sensitive Targets of Chlordane -- Inhalation ............................................... 6

1-4. Summary of Sensitive Targets of Chlordane -- Oral ....................................................... 7

2-1. Overview of the Number of Studies Examining Chlordane Health Effects ..................... 11

2-2. Levels of Significant Exposure to Chlordane – Inhalation .............................................. 16

2-3. Levels of Significant Exposure to Chlordane – Oral ...................................................... 34

3-1. Proposed Metabolic Pathways for Chlordane ................................................................. 79

5-1. Number of NPL Sites with Chlordane Contamination ..................................................... 91

6-1. Summary of Existing Health Effects Studies on Chlordane By Route and Endpoint ....... 154
LIST OF TABLES

1-1. Minimal Risk Levels (MRLs) for Chlordane Technical ................................................................. 8

2-1. Levels of Significant Exposure to Chlordane – Inhalation .......................................................... 12

2-2. Levels of Significant Exposure to Chlordane – Oral ................................................................. 20

2-3. Levels of Significant Exposure to Chlordane – Dermal ............................................................. 40

2-4. Genotoxicity of Chlordane \textit{In Vivo} .......................................................................................... 67

2-5. Genotoxicity of Chlordane \textit{In Vitro} ........................................................................................... 68

4-1. Chemical Identity of Chlordane ................................................................................................. 88

4-2. Physical and Chemical Properties of Chlordane ....................................................................... 90

5-1. Facilities that Produce, Process, or Use Chlordane .................................................................... 92

5-2. Releases to the Environment from Facilities that Produce, Process, or Use Chlordane ............... 95

5-3. Lowest Limit of Detection Based on Standards ......................................................................... 102

5-4. Summary of Environmental Levels of Chlordane ..................................................................... 102

5-5. Chlordane Levels in Water, Soil, and Air of National Priorities List (NPL) Sites ......................... 103

5-6. Detection of Chlordane in Air ................................................................................................... 104

5-7. Detection of Chlordane in Water and Sediments ....................................................................... 110

5-8. Detection of Chlordane in Soils ................................................................................................. 115

5-9. Detection of Chlordane in Food ............................................................................................... 120

5-10. Detection of Chlordane in Aquatic Organisms ....................................................................... 123

5-11. Detection of Chlordane in Terrestrial Organisms .................................................................... 127

5-12. Detection of Chlordane in Human Samples ............................................................................ 132

5-13. Chlordane Intake from Food .................................................................................................... 135

5-14. Geometric Mean and Selected Percentiles of Serum Oxychlordane (Lipid Adjusted) Serum Concentrations (in ng/g of Lipid or Parts per Billion on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004 ................................................................. 137
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-15.</td>
<td>Geometric Mean and Selected Percentiles of Serum Oxychlordane (Whole Weight) Serum Concentrations (in ng/g of Serum or Parts per Billion) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004.</td>
</tr>
<tr>
<td>5-16.</td>
<td>Geometric Mean and Selected Percentiles of Serum trans-Nonachlor (Lipid Adjusted) Serum Concentrations (in ng/g of Lipid or Parts per Billion on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004.</td>
</tr>
<tr>
<td>5-17.</td>
<td>Geometric Mean and Selected Percentiles of Serum trans-Nonachlor (Whole Weight) Serum Concentrations (in ng/g of Serum or Parts per Billion) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 1999–2004.</td>
</tr>
<tr>
<td>5-18.</td>
<td>Weighted Arithmetic Mean and Unadjusted Standard Error of Pooled Serum Concentrations of Serum Oxychlordane (Lipid Adjusted) (in ng/g of Lipid or Parts per Billion on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2005–2008.</td>
</tr>
<tr>
<td>5-19.</td>
<td>Weighted Arithmetic Mean and Unadjusted Standard Error of Pooled Serum Concentrations of Serum Oxychlordane (Whole Weight) (in ng/g of Serum or Parts per Billion) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2005–2008.</td>
</tr>
<tr>
<td>5-20.</td>
<td>Weighted Arithmetic Mean and Unadjusted Standard Error of Pooled Serum Concentrations of Serum trans-Nonachlor (Lipid Adjusted) (in ng/g of Lipid or Parts per Billion on a Lipid-Weight Basis) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2005–2008.</td>
</tr>
<tr>
<td>5-21.</td>
<td>Weighted Arithmetic Mean and Unadjusted Standard Error of Pooled Serum Concentrations of Serum trans-Nonachlor (Whole Weight) (in ng/g of Serum or Parts per Billion) for the U.S. Population from the National Health and Nutrition Examination Survey (NHANES) 2005–2008.</td>
</tr>
<tr>
<td>7-1.</td>
<td>Regulations and Guidelines Applicable to Chlordane.</td>
</tr>
</tbody>
</table>